Abnova (Taiwan)TPE:4133 -0.72%75 Operating Margin % is 5.71% as of Dec. 2025, which is 46% below its 10-year median of 10.50. GuruFocus rates TPE:4133 with a GF Score™ of 75/100 and a GF Value™ of NT$28.30 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 945 Biotechnology companies, Abnova (Taiwan) ranks better than 75.56% on this metric.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Abnova (Taiwan) Operating Margin % Related Terms
Abnova (Taiwan) Operating Margin % Historical Data
* Premium members only.
The historical data trend for Abnova (Taiwan)'s Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4133 vs VRTX, REGN, ALNY: Operating Margin % Comparison
For the Biotechnology subindustry, Abnova (Taiwan)'s Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abnova (Taiwan) Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abnova (Taiwan)'s Operating Margin % distribution charts can be found below:
* The bar in red indicates where Abnova (Taiwan)'s Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Abnova (Taiwan)'s Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abnova (Taiwan) (TPE:4133) has a Operating Margin % of 5.71% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Abnova (Taiwan) and its competitors. This is 46% below median its historical median of 10.50. Over the past decade, Abnova (Taiwan)'s Operating Margin % has ranged from 4.97 to 15.82. According to the industry distribution chart, Abnova (Taiwan) ranks #231 out of 945 companies in the Biotechnology industry, placing it in the top 24.4%.
Is Abnova (Taiwan)'s Operating Margin % too high?
Abnova (Taiwan)'s current Operating Margin % of 5.71% is 46% below median its 10-year median of 10.50. Over the past 10 years, this metric has ranged from a low of 4.97 to a high of 15.82. Based on the distribution chart, Abnova (Taiwan) ranks #231 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Abnova (Taiwan) has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abnova (Taiwan)'s Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abnova (Taiwan) ranks #231 out of 945 companies for Operating Margin %. This places Abnova (Taiwan) in the top 24% of its industry — outperforming the majority of peers. Historically, Abnova (Taiwan)'s own Operating Margin % has ranged from 4.97 to 15.82 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Abnova (Taiwan) and its competitors. Abnova (Taiwan)'s current Operating Margin % is 5.71%, which is 46% below median its own 10-year median of 10.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abnova (Taiwan) stock overvalued right now?
Based on GuruFocus' analysis, Abnova (Taiwan) (TPE:4133) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$28.30, compared to a current price of NT$20.55 — trading 27.4% below its estimated fair value. The current Operating Margin % is 5.71%, which is 46% below median its 10-year median of 10.50. Abnova (Taiwan)'s overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Abnova (Taiwan) (TPE:4133), the current Operating Margin % is 5.71% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abnova (Taiwan) (TPE:4133) Overvalued in 2026?
Based on GuruFocus' analysis, Abnova (Taiwan) stock appears to be undervalued.
The current stock price of NT$20.55 is trading 27.4% below its estimated GF Value™ of NT$28.30.
GuruFocus considers Abnova (Taiwan) to be Modestly Undervalued.
Key valuation signals for TPE:4133:
Operating Margin %: 5.71% (46% below median its 10-year median of 10.50)
GF Value™: NT$28.30 vs. price of NT$20.55 (27.4% below fair value)
No single metric tells the full story. See the TPE:4133 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abnova (Taiwan) Corp is engaged in developing, manufacturing, and selling monoclonal antibody, polyclonal antibody, proteins, medical inspection instruments and testing reagents, which are mainly antibody reagents, antibody chips or related products provided to and used by academic, research institutions or pharmaceutical factories. Geographically, it operates in America, Europe, Taiwan and Other Countries. It generates maximum revenue from America. Its products include: SARS-CoV/CoV-2, DNA, RNA new, Proteins/peptides, MaxPab, DNAxPab, Polyclonal Ab, Monoclonal Ab and Others. The company's services are: Gene synthesis & cytogenetics, Peptide services, Protein expression, Humanized antibody, Assay development, Conjugation, FFPE tumor tissue DNA, In situ hybridization (ISH) and Others.
75GF Score
Get the complete analysis for TPE:4133
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4133 has been successfully added to your 
